TrialCompass TCL
Back to results
Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07032532

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is evaluating Golidocitinib and Golidocitinib plus CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Golidocitinib (DRUG): Golidocitinib 150mg orally once daily in a 21-day cycle | Golidocitinib plus CHOP (DRUG): Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.

Drugs / treatments
Golidocitinib, Golidocitinib plus CHOP
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

NCT07032532

Phase: Phase 2 | Status: Not yet recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is evaluating Golidocitinib and Golidocitinib plus CHOP as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated
  • Must be well enough for treatment (adequate performance status)

What's being tested

Golidocitinib (DRUG): Golidocitinib 150mg orally once daily in a 21-day cycle | Golidocitinib plus CHOP (DRUG): Golidocitinib 150mg orally every other day with CHOP (Cyclophosphamide: 750mg/m2, IV, d1 ; Doxorubicin: 50mg/m2, IV, d1; Vincristine: 1.4mg/m2, IV, d1 ; Prednison: 100mg, po, d1-5) in a 21-day cycle for 6 cycles.

Drugs / treatments: Golidocitinib, Golidocitinib plus CHOP

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 35 patients

Primary endpoint: 2-year Progression-Free Survival Rate

Ages: 18 Years to —

Start date: 2025-07 | Est. completion: 2028-12

Locations

0 US sites · 1 total

Contact

Huiqiang Huang | huanghq@sysucc.org.cn | 020-87343350

Sponsor: Sun Yat-sen University (OTHER)

Tags

All T-cell lymphomas · Newly diagnosed

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT07032532

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.